Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Adipocytokine assessment may refine CV risk stratification in obesity; extends mechanistic understanding but leaves targeted therapies open.
Obesity is closely associated with an increased risk for metabolic and cardiovascular diseases. Adipose tissue produces a number of secretory bioactive substances, also known as adipocytokines or adipokines, which directly affect adjacent or distant organs. Most adipocytokines are pro-inflammatory, thereby promoting the obesity-linked disorders. In contrast, there are a small number of adipocytokines that exhibit antiinflammatory properties. It is now recognized that dysregulated production or secretion of adipocytokines caused by adipocyte dysfunction leads to the development of obesity-linked complications. In this review, we focus on the functional role of several adipocytokines in metabolic and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Ouchi et al. (2012) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: